Abstract
Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
